Lilly Expanding Access for People (LEAP)

Lilly Expanding Access for People (LEAP) targets diabetes in the emerging middle class in China.

Summary

  • What: Under LEAP, Eli Lilly is supporting training for primary care physicians in China to increase their confidence and skills to manage diabetes across all stages of the disease.
  • Details: It also aims to improve community-based care, by strengthening linkages between communities, township clinics and larger teaching hospitals, and empowering people to manage their disease.
  • Scope: LEAP is focusing on diabetes in the emerging middle class in China, with the intention to expand in other countries and disease areas.
  • Change: LEAP was initially implemented in six provinces in China, and now covers 13 provinces.

Looking closer

The LEAP programme has started in 2016 in China to target diabetes, with the intention to scale up in other disease areas and regions. The decision for starting this initiative in China is based on the fact that there are 100 million people with diabetes in China (one quarter of the world’s total).

LEAP uses the Shared Value approach to inform a for-profit business model and find new ways to extend the reach and impact of products to the emerging Chinese middle class. The Shared Value approach aims to develop future markets while also strengthening economies, the marketplace and communities.

This growing population segment – particularly in Asia and Africa – increasingly seeks, and is able to afford, quality healthcare services. LEAP is designed to meet patients’ and healthcare professionals’ (HCPs) needs through training and patient support, as well as through public-private partnerships with government departments.

The LEAP strategy, consistent with the company corporate strategy, is to: establish a new business approach that expands effective access to Lilly products and services by increasing the number of people currently served by Lilly’s core business model.

In communities where LEAP operates, some patients can access basic diabetes medicines including human insulins, but the healthcare clinics where they typically seek care are too often under-equipped to provide the right support and quality care for diabetes, which is a lifelong disease. Many HCPs working in these clinics lack the confidence and capability to effectively manage diabetes especially when it involves the prescription of insulin. Under LEAP, Lilly aims to ensure that primary care physicians receive improved training to increase their confidence and skills to manage diabetes across all stages of the disease. The programme also aims to improve community-based care by strengthening linkages between community and township clinics with diabetes experts and larger teaching hospitals, and empowering people to manage their disease with the support of Lilly Diabetes Educators.

LEAP was initially implemented in six provinces in China, and now covers 13 provinces. There are currently between 100-200 dedicated personnel supporting LEAP, with additional personnel providing indirect support. It is anticipated that this initiative will cover additional provinces in China in the future, and the company will evaluate potential opportunities to pursue similar work in other countries.

Sign up to receive updates about our work.